文献速递糖尿病

抗IL-21抗体联合利拉鲁肽用于新发1型糖尿病β细胞功能保护:2期随机双盲安慰剂对照试验

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2021-03-01

这项在17国94中心开展的2期双盲试验纳入308例18-45岁新诊断1型糖尿病成人,随机分四组。第54周时,抗IL-21抗体联合利拉鲁肽组MMTT刺激C肽下降幅度显著小于安慰剂组,单药组无显著差异;联合治疗安全性较好,但疗效在停药后减退。

要点

  • 抗IL-21联合利拉鲁肽可减缓新发1型糖尿病β细胞功能下降。
  • 单用抗IL-21或利拉鲁肽对C肽下降无显著改善。
  • 联合治疗安全性较好,未见糖尿病酮症酸中毒事件。

核心结论

  • 抗IL-21抗体联合利拉鲁肽可能保护新诊断1型糖尿病患者的β细胞功能。
  • 该联合疗效与其他疾病修饰干预试验相似,但安全性似乎更好。

研究设计与样本

  • 随机、平行组、安慰剂对照、双模拟、双盲2期试验,在17国94中心进行。
  • 纳入308例18-45岁新诊断1型糖尿病且残留β细胞功能的成人,1:1:1:1随机分四组。

主要发现

  • 停药后疗效减退;免疫细胞亚群变化轻微且短暂(随时间变化<10%)。

关键数值与推荐

  • 主要终点为第54周MMTT刺激C肽浓度4小时AUC相对基线的变化。
  • 最常见不良事件为胃肠道疾病,与利拉鲁肽已知副作用一致;活性组与安慰剂组低血糖事件率无显著差异,但治疗期利拉鲁肽组低于安慰剂组。
  • 未观察到糖尿病酮症酸中毒事件。

临床怎么用

  • 联合抗IL-21与利拉鲁肽可能作为新诊断1型糖尿病胰岛素辅助治疗以保护β细胞功能。
  • 需进一步3期试验评估疗效与安全性。

局限性

  • 疗效在治疗停止后减退。
  • 研究为2期试验,样本量有限,需3期验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Type 1 diabetes is characterised by progressive loss of functional β-cell mass, necessitating insulin treatment. We aimed to investigate the hypothesis that combining anti-interleukin (IL)-21 antibody (for low-grade and transient immunomodulation) with liraglutide (to improve β-cell function) could enable β-cell survival with a reduced risk of complications compared with traditional immunomodulation. METHODS: This randomised, parallel-group, placebo-controlled, double-dummy, double-blind, phase 2 trial was done at 94 sites (university hospitals and medical centres) in 17 countries. Eligible participants were adults aged 18-45 years with recently diagnosed type 1 diabetes and residual β-cell function. Individuals with unstable type 1 diabetes (defined by an episode of severe diabetic ketoacidosis within 2 weeks of enrolment) or active or latent chronic infections were excluded. Participants were randomly assigned (1:1:1:1), with stratification by baseline stimulated peak C-peptide concentration (mixed-meal tolerance test [MMTT]), to the combination of anti-IL-21 and liraglutide, anti-IL-21 alone, liraglutide alone, or placebo, all as an adjunct to insulin. Investigators, participants, and funder personnel were masked throughout the treatment period. The primary outcome was the change in MMTT-stimulated C-peptide concentration at week 54 (end of treatment) relative to baseline, measured via the area under the concentration-time curve (AUC) over a 4 h period for the full analysis set (intention-to-treat population consisting of all participants who were randomly assigned). After treatment cessation, participants were followed up for an additional 26-week off-treatment observation period. This trial is registered with ClinicalTrials.gov, NCT02443155. FINDINGS: Between Nov 10, 2015, and Feb 27, 2019, 553 adults were assessed for eligibility, of whom 308 were randomly assigned to receive either anti-IL-21 plus liraglutide, anti-IL-21, liraglutide, or placebo (77 assigned to each group). Compared with placebo (ratio to baseline 0·61, 39% decrease), the decrease in MMTT-stimulated C-peptide concentration from baseline to week 54 was significantly smaller with combination treatment (0·90, 10% decrease; estimated treatment ratio 1·48, 95% CI 1·16-1·89; p=0·0017), but not with anti-IL-21 alone (1·23, 0·97-1·57; p=0·093) or liraglutide alone (1·12, 0·87-1·42; p=0·38). Despite greater insulin use in the placebo group, the decrease in HbA1c (a key secondary outcome) at week 54 was greater with all active treatments (-0·50 percentage points) than with placebo (-0·10 percentage points), although the differences versus placebo were not significant. The effects diminished upon treatment cessation. Changes in immune cell subsets across groups were transient and mild (<10% change over time). The most frequently reported adverse events included gastrointestinal disorders, in keeping with the known side-effect profile of liraglutide. The rate of hypoglycaemic events did not differ significantly between active treatment groups and placebo, with an exception of a lower rate in the liraglutide group than in the placebo group during the treatment period. No events of diabetic ketoacidosis were observed. One participant died while on liraglutide (considered unlikely to be related to trial treatment) in connection with three reported adverse events (hypoglycaemic coma, pneumonia, and brain oedema). INTERPRETATION: The combination of anti-IL-21 and liraglutide could preserve β-cell function in recently diagnosed type 1 diabetes. The efficacy of this combination appears to be similar to that seen in trials of other disease-modifying interventions in type 1 diabetes, but with a seemingly better safety profile. Efficacy and safety should be further evaluated in a phase 3 trial programme. FUNDING: Novo Nordisk.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. von Herrath M, Bain SC, Bode B, et al. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021. PMID: 33662334. doi:10.1016/S2213-8587(21)00019-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。